- Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenCondition: Pediatric Growth Hormone Deficiency
Interventions: Drug: MOD-4023; Drug: Somatropin
Sponsors: Prolor Biotech, Inc.; Prolor Biotech, Inc.
Recruiting - verified May 2012 - Condition: Achondroplasia
Interventions: Drug: BMN 111; Drug: Normal Saline
Sponsors: BioMarin Pharmaceutical; BioMarin Pharmaceutical
Recruiting - verified May 2012 - Conditions: Silver Russell Syndrome; Prader-Willi Syndrome
Interventions: Drug: Anastrozole; Drug: Placebo
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified January 2012 - Conditions: Adult Growth Hormone Deficiency; Growth Hormone Deficiency in Children; Healthy
Interventions: Drug: NNC0195-0092; Drug: placebo; Drug: NNC0195-0092; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Conditions: Growth Hormone Deficiency; Healthy
Interventions: Drug: somatropin; Drug: somatropin
Sponsors: Novo Nordisk; Novo Nordisk
Not yet recruiting - verified March 2012 - Conditions: Adrenal Hyperplasia, Congenital; Congenital Hypothyroidism; Cystic Fibrosis
Intervention:
Sponsors: Luminex Molecular Diagnostics; Luminex Corporation
Recruiting - verified January 2012 - Condition: Growth Hormone Deficiency
Interventions: Drug: Somatropin; Drug: Placebo
Sponsors: HanAll BioPharma Co., Ltd.; HanAll BioPharma Co., Ltd.
Recruiting - verified September 2011 - Condition: Idiopathic Short Stature
Intervention: Drug: Nutropin [Somatropin (rDNA origin) for injection]
Sponsors: Ipsen; Ipsen
Not yet recruiting - verified April 2012 - Conditions: Idiopathic Growth Hormone Deficiency; Turner Syndrome
Intervention: Other: Blood sampling
Sponsors: Merck KGaA; Merck KGaA; Merck Serono S.A., Geneva
Recruiting - verified May 2012 - Conditions: Iodine Deficiency; Goiter; Cretinism
Intervention: Other: Iodized salt
Sponsors: McGill University; McGill University; MicroNutrient Initiative; Ethiopian Health and Nutrition Research Institute (EHNRI)
Recruiting - verified February 2012 - Condition: Acromegaly
Intervention: Procedure: echocardiogram
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified May 2012 - Conditions: Adult Growth Hormone Deficiency; Hypothalamic-pituitary Disorders
Interventions: Procedure: Glucagon stimulation test and insulin tolerance test; Procedure: glucagon stimulation test and insulin tolerance test
Sponsors: The Cleveland Clinic; The Cleveland Clinic; Massachusetts General Hospital; Allegheny Endocrinology Associates; Oregon Health and Science University
Recruiting - verified January 2011 - Conditions: Idiopathic Short Stature; Self Image
Interventions: Drug: GH treatment (Genotropin); Drug: 1 year treatment with placebo followed by optional 3 years of GH treatment; Other: Non treatment group; Other: Normal stature control group
Sponsors: Rabin Medical Center; Rabin Medical Center; Pfizer
Recruiting - verified December 2011 - Conditions: Obesity; Short Stature
Interventions: Drug: Niacin; Drug: Placebo
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified April 2012 - Condition: Idiopathic Short Stature
Interventions: Drug: Anastrozole and Letrozole; Drug: Somatropin; Drug: Aromatase inhibitor and somatropin
Sponsors: Nemours Children's Clinic; Nemours Children's Clinic; Thrasher Research Fund; Genentech; Novartis; AstraZeneca
Recruiting - verified May 2012 - Condition: Growth Hormone Deficiency
Intervention: Drug: Norditropin SimpleXx (growth hormone)
Sponsors: Aarhus University Hospital; Aarhus University Hospital; Novo Nordisk
Recruiting - verified June 2011 - Conditions: Growth Hormone Deficiency; Traumatic Brain Injury
Interventions: Drug: Human Growth Hormone; Drug: Placebo
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; The Moody Foundation
Recruiting - verified December 2011 - Condition: Severe Primary Insulin-like Growth Factor-1 Deficiency
Intervention: Biological: mecasermin [rDNA origin] injection
Sponsors: Ipsen; Ipsen
Recruiting - verified April 2012 - Condition: Growth Hormone Deficiency
Interventions: Drug: Recombinant Human Growth Hormone; Drug: Recombinant human IGF-1
Sponsors: Columbia University; Columbia University; Tercica
Recruiting - verified January 2012 - Condition: Short Stature
Interventions: Behavioral: growth hormone- Genotropin or NorditropinSimplex and nutritional intervention; Behavioral: growth hormone-Genotropin or NorditropinSimplex or Biotropin
Sponsors: Rabin Medical Center; Rabin Medical Center
Recruiting - verified October 2011 - Conditions: Growth Hormone Deficiency; Septo-Optic Dysplasia; Hypopituitarism
Intervention: Drug: Nutropin AQ
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles; Genentech
Recruiting - verified February 2012 - Condition: Fetal Growth Retardation
Intervention: Drug: somatropin (rDNA)
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified July 2011 - Conditions: Dwarfism; Osteogenesis Imperfecta
Interventions: Drug: Humatrope; Drug: GRH; Drug: Nutropin
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified July 2011 - Conditions: Dwarfism; Osteogenesis Imperfecta
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified September 2011 - Conditions: Cockayne Syndrome; Skin Neoplasm; Xeroderma Pigmentosum
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified June 2011
 |
Join Clinical trials for Dwarfism |
